Announcement • May 07

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

ZIVO Bioscience, Inc. announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirmed earlier observations that ZIVO's active ingredients may positively influence LPAI transmission dynamics, while identifying the optimal formulation for further testing. In the first arm of the study, which involved birds receiving a direct challenge with LPAI, modest positive trends were observed in viral shedding reduction among ZIVO-treated groups compared with untreated controls. While these differences did not reach statistical significance, the findings suggest potential for ZIVO's formulations to lessen disease severity. Notably, the formulation consisting of a blend of four distinct algal-derived materials demonstrated a slower and less efficient spread of the virus. One bird treated with this combination showed no signs of infection post-exposure, indicating potential protective effects. These findings resulting from rigorous testing at the University of Delaware reinforce commitment to developing sustainable, non-antibiotic solutions for the poultry industry. The insights gained from this study show encouraging trends and identifying a superior formulation will be instrumental in guiding future research and product optimization efforts. Given the potential impact ZIVO's product can have on mitigating Avian influenza, a widespread issue in the nation's large poultry industry, the company submitted a funding request to the State of Michigan for $5.5 million to further research. Additionally, the company are applying for a portion of the previously announced $100 million Avian Influenza Poultry Innovation Grand Challenge from the USDA.

Announcement • Dec 21

ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

Zivo Bioscience, Inc. reported favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Key findings of statistical significance from the study include: A reduction in viral titers (viral shedding) in infected birds receiving ZIVO's products compared with untreated infected controls. A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease. The two-part controlled study evaluated the efficacy of ZIVO's proprietary Active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO's proprietary active ingredient that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO's products limit viral replication within a host. These favorable results indicate that ZIVO's proprietary active Ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health. Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study's positive outcomes justify further research and product development, supporting the potential of ZIVO' pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry. "The University of Delaware's findings provide compelling evidence that its feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry".

ZIVO Bioscience, Inc. Stock Price

ZIVO Share Price Performance

ZIVO Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

ZIVO Bioscience, Inc. Key Details

About ZIVO

Recent ZIVO News & Updates

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

ZIVO Bioscience, Inc., Annual General Meeting, Jun 09, 2025

ZIVO Bioscience, Inc. Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

Recent updates

ZIVO Bioscience, Inc. Competitors

China Foods Holdings

Healthy Extracts

Mannatech

Big Tree Cloud Holdings